Jump to content

Draft:Payam A. Gammage

From Wikipedia, the free encyclopedia
  • Comment: Well done on creating the draft, and it may potentially meet the relevant requirements (including WP:GNG, WP:ANYBIO, WP:NPROF) but presently it is not clear that it does.
    As other reviewers have noted, Wikipedia's basic requirement for entry is that the subject is notable. Essentially subjects are presumed notable if they have received significant coverage in multiple published secondary sources that are reliable, intellectually independent of each other, and independent of the subject. To properly create such a draft page, please see the articles ‘Your First Article’, ‘Referencing for Beginners’ and ‘Easier Referencing for Beginners’.
    Please note that many of the references are not from sources that are considered reliable for establishing notability and should be removed (including articles by Pamaym as opposed to articles, from reliable sources, about him).
    Additionally, the draft tends to read too much like a CV, which Wikipedia is not.
    Also, if you have any connection to the subject, including being paid, you have a conflict of interest that you must declare on your Talk page (to see instructions on how to do this please click the link).
    Please familiarise yourself with these pages before amending the draft. If you feel you can meet these requirements, then please make the necessary amendments before resubmitting the page. It would help our volunteer reviewers by identifying, on the draft's talk page, the WP:THREE best sources that establish notability of the subject.
    It would also be helpful if you could please identify with specificity, exactly which criteria you believe the page meets (eg "I think the page now meets WP:NPROF criteria #3, because XXXXX").
    You may also wish to leave a note for me on my talk page and I would be happy to reassess. Cabrils (talk) 04:55, 6 July 2024 (UTC)
  • Comment: Please remove all inline external links from body text; convert to citations where relevant. There should be no links pointing to external resources until the footnotes in the 'References' section. DoubleGrazing (talk) 13:46, 4 July 2024 (UTC)
  • Comment: The sources are insufficient for establishing notability per WP:GNG. If WP:NACADEMIC notability is being claimed instead, please make it clear which of the eight criteria is met, and what evidence supports this.
    In articles on living people, every material statement, anything potentially contentious, and all private personal details must be clearly supported by inline citations to reliable published sources, or else removed. Currently only the 'Research' section is referenced. DoubleGrazing (talk) 13:45, 4 July 2024 (UTC)
Payam A. Gammage
Born1987 (36 years old)
Exeter, United Kingdom
Alma materUniversity College London (M.Sci.) University of Cambridge (Ph.D.)
Known formitochondrial genome editing, mitochondrial genetics of cancer
AwardsEuropean Research Council Starting Grant

National Cancer Institute R37 MERIT Award

European Molecular Biology Organistaion (EMBO) Young Investigator Award
Scientific career
FieldsMitochondrial genome engineering, mitochondrial genetics, cancer metabolism, tumour biology
InstitutionsUniversity of Cambridge

University of Glasgow

Cancer Research UK Beatson Institute
Websitehttps://www.crukscotlandinstitute.ac.uk/cruk-si-research/cruk-si-research-groups/payam-gammage-mitochondrial-oncogenetics.html

Payam A. Gammage is a British scientist, Group Leader at the Cancer Research UK Scotland Institute (Formerly Beatson Institute) and Professor of Mitochondrial Biology at the University of Glasgow.

Education[edit]

Gammage received his M.Sci. degree in Neuroscience from University College London, where he developed an interest in mitochondrial biology during initial research training at the Institute of Neurology. As a graduate student at the MRC Mitochondrial Biology Unit, he went on to receive his Ph.D. degree in Biochemistry from the University of Cambridge, and was appointed as a MRC Career Development Fellow to pursue postdoctoral training within the MRC Mitochondrial Biology Unit.

Following postdoctoral training, Gammage was appointed as a Group Leader at the Cancer Research UK Beatson Institute (now Scotland Institute) in 2019, where he founded the Mitochondrial Oncogenetics Laboratory. He holds a joint appointment as Professor of Mitochondrial Biology at the University of Glasgow.[1]

Research[edit]

Gammage has pioneered the adaptation of genome engineering tools to manipulate mitochondrial DNA (mtDNA) in mammals. His inventions in this field are described in highly cited papers detailing the development of engineered genome editing tools capable of manipulating mtDNA across entire organs[2][3][4], with both clinical and experimental application[5][6][7]. Together with Dr Eduard Reznik, Memorial Sloan Kettering Cancer Center, he discovered the recurrence and selective pressures operating on mtDNA mutations, found in approximately half of all cancers, and how these are associated with significantly improved patient outcomes in the context of colorectal cancer.[8][9][10][11] He further discovered the impact of recurrent mtDNA mutation in melanoma, likely explaining a significant proportion of the Warburg Effect and providing new insights into the immunological response to cancer immunotherapies.[12][13][14][15][16][17][18]

Awards & Recognition[edit]

Gammage was awarded a European Research Council (ERC) Starting Grant in 2021[19]. He is the recipient of a National Institutes of Health, National Cancer Institute MERIT Award (R37) and the European Molecular Biology Organization (EMBO) Young Investigator Award.[20] Gammage currently serves on the Editorial Board of The Royal Society Open Science.[21]

References[edit]

  1. ^ "Payam Gammage - Mitochondrial Oncogenetics". www.crukscotlandinstitute.ac.uk. Retrieved 2024-07-05.
  2. ^ Gammage, Payam A; Rorbach, Joanna; Vincent, Anna I; Rebar, Edward J; Minczuk, Michal (April 2014). "Mitochondrially targeted ZFN s for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations". EMBO Molecular Medicine. 6 (4): 458–466. doi:10.1002/emmm.201303672. ISSN 1757-4676. PMC 3992073. PMID 24567072.
  3. ^ Gammage, Payam A.; Viscomi, Carlo; Simard, Marie-Lune; Costa, Ana S. H.; Gaude, Edoardo; Powell, Christopher A.; Van Haute, Lindsey; McCann, Beverly J.; Rebelo-Guiomar, Pedro; Cerutti, Raffaele; Zhang, Lei; Rebar, Edward J.; Zeviani, Massimo; Frezza, Christian; Stewart, James B. (November 2018). "Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo". Nature Medicine. 24 (11): 1691–1695. doi:10.1038/s41591-018-0165-9. ISSN 1546-170X. PMC 6225988. PMID 30250142.
  4. ^ "Google Patents". patents.google.com. Retrieved 2024-07-04.
  5. ^ Leslie, Mitch (24 September 2018). "Zapping mutant DNA in mitochondria could treat major class of genetic disease". Science Magazine.
  6. ^ Crunkhorn, Sarah (30 October 2018). "Eliminating mutant mitochondrial DNA". Nature Reviews Drug Discovery. 17 (11): 788. doi:10.1038/nrd.2018.190. ISSN 1474-1784. PMID 30374185.
  7. ^ Brooks, Helen R. (1 November 2018). "Mitochondria: Finding the Power to Change". Cell. 175 (4): 891–893. doi:10.1016/j.cell.2018.10.035. ISSN 0092-8674. PMID 30388445.
  8. ^ Gorelick, Alexander N.; Kim, Minsoo; Chatila, Walid K.; La, Konnor; Hakimi, A. Ari; Berger, Michael F.; Taylor, Barry S.; Gammage, Payam A.; Reznik, Ed (April 2021). "Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA". Nature Metabolism. 3 (4): 558–570. doi:10.1038/s42255-021-00378-8. ISSN 2522-5812. PMC 9304985. PMID 33833465.
  9. ^ "Hiding in Plain Sight: Mitochondrial DNA May Hold Overlooked Cancer Clues | Memorial Sloan Kettering Cancer Center". www.mskcc.org. 2021-04-23. Retrieved 2024-07-05.
  10. ^ "Mutations in overlooked DNA could have profound impact on survival for bowel cancer patients". EurekAlert!. Retrieved 2024-07-05.
  11. ^ "Overlooked DNA mutations 'may increase bowel cancer patients' survival chances'". The Irish News. 2021-04-08. Retrieved 2024-07-05.
  12. ^ Mahmood, Mahnoor; Liu, Eric Minwei; Shergold, Amy L.; Tolla, Elisabetta; Tait-Mulder, Jacqueline; Huerta-Uribe, Alejandro; Shokry, Engy; Young, Alex L.; Lilla, Sergio; Kim, Minsoo; Park, Tricia; Boscenco, Sonia; Manchon, Javier L.; Rodríguez-Antona, Crístina; Walters, Rowan C. (April 2024). "Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma". Nature Cancer. 5 (4): 659–672. doi:10.1038/s43018-023-00721-w. ISSN 2662-1347. PMC 11056318. PMID 38286828.
  13. ^ Enríquez, José A.; Mittelbrunn, María (2024-07-02). "Warburg Effect Reshapes Tumor Immunogenicity". Cancer Research. 84 (13): 2043–2045. doi:10.1158/0008-5472.CAN-24-1304. ISSN 0008-5472. PMID 38657107.
  14. ^ Gunn, Tim (2024-01-31). "The secret in cancer cells that can make immunotherapy more effective". Cancer Research UK - Cancer News. Retrieved 2024-07-05.
  15. ^ "Improving cancer treatment by exploiting mtDNA mutations". Drug Target Review. Retrieved 2024-07-05.
  16. ^ "MSN". www.msn.com. Retrieved 2024-07-05.
  17. ^ "Cancer Patients With Mutated Mitochondria Respond Better to Treatment". The Epoch Times. 2024-01-30. Retrieved 2024-07-05.
  18. ^ "Cancer treatment two and a half times more effective when tumours have defective "energy factories"". EurekAlert!. Retrieved 2024-07-05.
  19. ^ ERC (6 January 2022). "European Research Council" (PDF). European Research Council.
  20. ^ "EMBO announces new Young Investigators – Press releases – EMBO". 2023-12-05. Retrieved 2024-07-05.
  21. ^ "The Royal Society - Open Science".
Retrieved from "https://wiki.riteme.site/w/index.php?title=Draft:Payam_A._Gammage&oldid=1233030696"